|

GH21 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Suzhou Genhouse Bio Co., Ltd.2

Indications

  • Cancer2
  • Non-Small Cell Lung Cancer With EGFR Mutation1
  • Advanced Solid Tumor With Oncogenic Driver Mutations1
  • Patients With Advanced Solid Tumor1
  • Lung Cancer1

Other2 trials

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
Phase 1/2
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.